[Impact of molecular targeting therapy on tumor immunity].
Emerging evidence has been unveiled that major oncogenic pathways, which serve as a main focus for the molecular targeting therapies, play a pivotal role in establishing immunosuppressive tumor microenvironments. The modulation of various immune modulatory pathways, such as upregulation of PD-L1 by various oncogenic mutations such as EGFR, BRAF, activation of PI3K and JAK-Stat3 on tumor cells, may be critical in modulating tumor immune responses. Given the potential clinical impact of immune checkpoint blockade and other immunotherapeutic regimens as a future anticancer regimen, it is critical to clarify the mechanisms by which molecularly targetable oncogenes and tumor microenvironments influence quality of tumor immunosurveillance, which should provide a new strategy for suitable combinatorial approaches composing of molecular targeting and immunotherapies.
Masahisa
M
Jinushi
Hirotoshi
H
Akita
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen / Q000235:genetics / Q000378:metabolism; D060908:CTLA-4 Antigen; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D007157:Immunologic Surveillance; D000074324:Ipilimumab; D053612:Janus Kinases / Q000378:metabolism; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D000077594:Nivolumab; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism; D050796:STAT3 Transcription Factor; D059016:Tumor Microenvironment / Q000276:immunology*; D015854:Up-Regulation
D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D000077594:Nivolumab; D019869:Phosphatidylinositol 3-Kinases; C512478:EGFR protein, human; D066246:ErbB Receptors; D053612:Janus Kinases; D048493:Proto-Oncogene Proteins B-raf